Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18503202 | 0.91 | MEN1 (0.33) | HRH3MEN1CYP3A4ALOX15KMT2A | |
| SCHEMBL18419061 | 0.87 | LMNA (0.46) | HRH3MEN1CYP3A4ALOX15KMT2A | |
| SCHEMBL18503336 | 0.84 | LMNA (0.48) | HRH3MEN1CYP3A4ALOX15KMT2A | |
| SCHEMBL18512665 | 0.83 | TSHR (0.43) | MEN1CYP3A4KMT2ALMNATSHR | |
| SCHEMBL18512393 | 0.82 | LMNA (0.40) | LMNATSHR | |
| SCHEMBL21226053 | 0.81 | LMNA (0.43) | HRH3MEN1CYP3A4ALOX15KMT2A | |
| SCHEMBL1426138 | 0.80 | TSHR (0.46) | MEN1CYP3A4ALOX15KMT2ALMNA | |
| SCHEMBL22268987 | 0.80 | LMNA (0.31) | LMNA | |
| SCHEMBL20509870 | 0.78 | LMNA (0.40) | MEN1CYP3A4ALOX15KMT2ALMNA | |
| SCHEMBL17615514 | 0.78 | HRH3 (0.42) | HRH3MEN1CYP3A4KMT2ATSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240207299-A1 | PYRROLOPYRIMIDINE NUCLEOSIDES FOR TREATING OR PREVENTING A SARS-COV-2 INFECTION | CHIMERIX, INC. (US) | 2024-06-27 | — | — | US | disclosed |
| US-20170253628-A1 | PYRROLOPYRIMIDINE NUCLEOSIDES AND ANALOGS THEREOF | U.S. BANK TRUST COMPANY, NATIONAL ASSOCIATION, AS COLLATERAL TRUSTEE | 2017-09-07 | — | — | US | disclosed |
| US-9708359-B2 | Pyrrolopyrimidine nucleosides and analogs thereof | CHIMERIX, INC. (US) | 2017-07-18 | — | — | US | disclosed |
| US-9701706-B2 | Pyrrolopyrimidine nucleosides and analogs thereof | CHIMERIX, INC. (US) | 2017-07-11 | — | — | US | disclosed |
| US-20170137454-A1 | PYRROLOPYRIMIDINE NUCLEOSIDES AND ANALOGS THEREOF | U.S. BANK TRUST COMPANY, NATIONAL ASSOCIATION, AS COLLATERAL TRUSTEE | 2017-05-18 | — | — | US | disclosed |
| US-20170044202-A1 | PYRROLOPYRIMIDINE NUCLEOSIDES AND ANALOGS THEREOF | U.S. BANK TRUST COMPANY, NATIONAL ASSOCIATION, AS COLLATERAL TRUSTEE | 2017-02-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170137454-A1 | PYRROLOPYRIMIDINE NUCLEOSIDES AND ANALOGS THEREOF | TYMP, PNP, DPYD | HRH3 4426/4885MEN1 3288/4885CYP3A4 1454/4885 |
| US-20170253628-A1 | PYRROLOPYRIMIDINE NUCLEOSIDES AND ANALOGS THEREOF | TYMP, PNP, DPYD | HRH3 4426/4885MEN1 3288/4885CYP3A4 1454/4885 |
| US-20170044202-A1 | PYRROLOPYRIMIDINE NUCLEOSIDES AND ANALOGS THEREOF | TYMP, ITPA, IMPDH1 | HRH3 4431/4885MEN1 3416/4885CYP3A4 1800/4885 |
| US-20240207299-A1 | PYRROLOPYRIMIDINE NUCLEOSIDES FOR TREATING OR PREVENTING A SARS-COV-2 INFECTION | PNP, ACE2, TYMP | HRH3 4439/4885MEN1 4367/4885CYP3A4 733/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.